Engerix-B Market (Prophylactic Hepatitis B Virus Vaccines) Analysis and Forecast to 2022 adds report “Engerix-B (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022” to its store.

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Request a sample copy of this report @ .

Engerix-B [Hepatitis B Vaccine (Recombinant)] is GSK’s monovalent vaccine that protects children, adolescents, and adults against acute and chronic infections caused by all known strains of HBV. Following the 1986 debut of Merck’s hepatitis B offering, Recombivax HB, Engerix-B was the second recombinant HBV vaccine to receive FDA approval. Engerix-B also received market authorization in Canada in 1991 and the 5EU in 2000. It is marketed under the names Engerix-B Kinder/Engerix-B Erwachsene in Germany.


  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Engerix-B including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Engerix-B for top seven countries from 2012 to 2022.
  • Sales information covered for the US, Canada, France, Germany, Italy, Spain and the UK

Complete report is available @ .

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Engerix-B performance
  • Obtain sales forecast for Engerix-B from 2012-2022 in the top seven countries (the US, Canada, France, Germany, Italy, Spain and the UK).

Table of Contents

1 Table of Contents 6
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12

Inquire for discount on this report @ .

3 Disease Overview 13
3.1 Overview 13
3.2 Etiology and Pathophysiology 14
3.2.1 Etiology 14
3.2.2 Pathophysiology 17
3.3 Symptoms 19
3.4 Prognosis 21

4 Vaccination Recommendations and Coverage Rates 22
4.1 Overview 22

5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 26

6 Engerix-B 29
6.1 Overview 29
6.2 Immunogenicity 31
6.3 Safety 32
6.4 SWOT Analysis 33
6.5 Forecast 34

Purchase a copy of this report @ .

Browse Hepatitis Drugs Industry Reports @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter :!/RnRMR

Facebook :

Google Plus :